Andy Batts
Long only, value, growth, momentum

Luminex: Over-Pessimism Could Be An Opportunity With Upcoming Catalysts

Shareholders of Luminex Corporation (NASDAQ:LMNX) have seen a range-bound movement in the stock over the years. In 2013 LMNX underperformed the overall market, particularly the biotech sector, due to the fact that the life science research and the molecular diagnostic markets were experiencing a temporary deceleration. However, 2014 is looking like a big year for LMNX, with the company's advanced xMAP, xTAG and MultiCode technologies gaining momentum. Moreover, the company has a healthy pipeline including Project ARIES, its next-generation integrated molecular diagnostics system that is expected to be rolled out in 2014.

While the company would continue to face some risks associated with the underutilization of molecular assays due to budget sequestration in the United States, particularly in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details